Zacks: Analysts Anticipate ADMA Biologics Inc (ADMA) to Announce -$0.31 EPS
Wall Street brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to announce earnings of ($0.31) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.32) to ($0.29). ADMA Biologics reported earnings per share of $0.59 during the same quarter last year, which would suggest a negative year-over-year growth rate of 152.5%. The business is scheduled to issue its next earnings report on Friday, November 2nd.
On average, analysts expect that ADMA Biologics will report full year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.43) to ($1.26). For the next year, analysts anticipate that the company will report earnings of ($0.53) per share, with EPS estimates ranging from ($0.93) to $0.00. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for ADMA Biologics.
ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%. The business had revenue of $4.66 million for the quarter, compared to the consensus estimate of $5.35 million.
ADMA stock traded down $0.18 during midday trading on Friday, reaching $6.24. 3,350 shares of the company’s stock traded hands, compared to its average volume of 180,119. The stock has a market capitalization of $291.54 million, a price-to-earnings ratio of -3.35 and a beta of 2.35. ADMA Biologics has a 52 week low of $2.01 and a 52 week high of $6.96. The company has a debt-to-equity ratio of 0.79, a current ratio of 10.65 and a quick ratio of 8.88.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADMA. Millennium Management LLC increased its stake in ADMA Biologics by 254.0% in the fourth quarter. Millennium Management LLC now owns 67,533 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 48,455 shares during the last quarter. BlackRock Inc. increased its stake in ADMA Biologics by 59.5% in the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 15,115 shares during the last quarter. Spark Investment Management LLC bought a new position in ADMA Biologics in the first quarter valued at $102,000. JPMorgan Chase & Co. bought a new position in ADMA Biologics in the first quarter valued at $182,000. Finally, Element Capital Management LLC bought a new position in ADMA Biologics in the first quarter valued at $118,000. 55.08% of the stock is currently owned by institutional investors and hedge funds.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.